IO102-IO103 + pembrolizumab
Advanced Melanoma
Phase 1/2Completed
Key Facts
About IO Biotech
IO Biotech is developing a new class of therapeutic cancer vaccines based on its proprietary T-win® technology, which targets immune-suppressive molecules like IDO1 and PD-L1. The company's lead candidate, IO102-IO103 (Cylembio®), has shown promising clinical activity in combination with anti-PD-1 therapy in advanced melanoma. Following a strategic review and recent corporate restructuring, IO Biotech is exploring strategic alternatives to advance its pipeline.
View full company profileTherapeutic Areas
Other Advanced Melanoma Drugs
| Drug | Company | Phase |
|---|---|---|
| RP1 (vusolimogene odeparepvec) + nivolumab | Replimune | Phase 3 |